Abstract: Provided is a special Drosophila strain having a Bradeion gene artificially incorporated therein to exclusively express the gene in the compound eyes and thus to exhibit rough eye. The Drosophila strain has the following properties: (a) a human-derived Bradeion gene has been transferred in the strain to express the human-derived protein Bradeion in the compound eyes from the developmental period; (b) the compound eyes show morphological abnormality due to the expression of Bradeion; and (c) the morphological abnormality occurring in the compound eyes is multiplied according to the number of transferred Bradeion genes.

Abstract: The present invention relates to a chimeric mouse having an endogenous Bradeion gene, the gene expression of which has been suppressed, and a cell derived from a mouse embryonic stem cell, which is collected from such chimeric mouse.

Abstract: A human-derived bradeion protein, which has the following properties: (i) it is a transmembranous protein; (ii) it has a structure characteristic of growth hormone and cytokine receptors even in a structure of its transmembranous portion when its structure is determined by a hydrophobicity analysis according to Kyte-Doolittle method; (iii) it is expressed at a high level in a human adult brain, and in less amount in the heart, while it is not expressed in other adult organs or fetus; (iv) it induces programmed cell death (apoptosis) when over-expressed in a cultured human nerve cell lines; (v) it induces termination of cell division and aging when over-expressed in a cultured human normal cell; (vi) it is located in cytoplasm, and forms an intracellular aggregate when overexpressed; and (vii) besides human adult neurons, it is specifically expressed in a human colorectal cancer cell line or in a skin cancer cell line, or an analogue thereof.

Abstract: This invention relates to: a set of ribozymes which comprises at least one ribozyme capable of binding and cleaving Bradeion ? mRNA which corresponds to DNA comprising a nucleotide sequence shown in SEQ ID NO:1, and at least one ribozyme capable of binding to and cleaving Bradeion ? mRNA which corresponds to DNA comprising a nucleotide sequence shown in SEQ ID NO:3; a set of vectors comprising ribozymes; a pharmaceutical composition comprising set of vectors; and a method for treating a subject with a cancer using set of vectors.

Abstract: A human-derived bradeion protein, which has the following properties: (i) it is a transmembranous protein; (ii) it has a structure characteristic of growth hormone and cytokine receptors even in a structure of its transmembranous portion when its structure is determined by a hydrophobicity analysis according to Kyte-Doolittle method; (iii) it is expressed at a high level in a human adult brain, and in less amount in the heart, while it is not expressed in other adult organs or fetus; (iv) it induces programmed cell death (apoptosis) when over-expressed in a cultured human nerve cell lines; (v) it induces termination of cell division and aging when over-expressed in a cultured human normal cell; (vi) it is located in cytoplasm, and forms an intracellular aggregate when overexpressed; and (vii) besides human adult neurons, it is specifically expressed in a human colorectal cancer cell line or in a skin cancer cell line, or an analogue thereof.

Abstract: This invention relates to a human-derived bradeion protein having the following properties: (i) it is a transmembranous protein; (ii) it has a transmembranous portion, an extracellular portion, and a cytoplasmic portion in its molecule as determined by a hydrophobicity analysis according to Kyte-Doolittle method; (iii) it is expressed in the human adult normal brain and heart, the expression level thereof in the heart being about 10% or lower of that in the brain, while it is not expressed in other adult normal organs of spleen, lung, liver, skeletal muscle, kidney and pancreas, and in fetal brain, lung, heart and kidney; (iv) it induces programmed cell death when over-expressed in a cultured human brain-derived undifferentiated nerve cell line; (v) it induces termination of cell division and aging when over-expressed in a cultured human brain-derived differentiated nerve cell; (vi) it is located in cytoplasm in the course of the induced cell death, and forms an intracellular aggregate when overexpressed;

Abstract: Provided is a special Drosophila strain having a Bradeion gene artificially incorporated therein to exclusively express the gene in the compound eyes and thus to exhibit rough eye.

Abstract: This invention relates to a human-derived bradeion protein having the following properties:

Abstract: A human-derived bradeion protein, which has the following properties: (i) it is a transmembranous protein; (ii) it has a structure characteristic of growth hormone and cytokine receptors even in a structure of its transmembranous portion when its structure is determined by a hydrophobicity analysis according to Kyte-Doolittle method; (iii) it is expressed at a high level in a human adult brain, and in less amount in the heart, while it is not expressed in other adult organs or fetus; (iv) it induces programmed cell death (apoptosis) when over-expressed in a cultured human nerve cell lines; (v) it induces termination of cell division and aging when over-expressed in a cultured human normal cell; (vi) it is located in cytoplasm, and forms an intracellular aggregate when overexpressed; and (vii) besides human adult neurons, it is specifically expressed in a human colorectal cancer cell line or in a skin cancer cell line, or an analogue thereof.

Abstract: A human-derived bradeion protein, which has the following properties: (i) it is a transmembranous protein; (ii) it has a structure characteristic of growth hormone and cytokine receptors even in a structure of its transmembranous portion when its structure is determined by a hydrophobicity analysis according to Kyte-Doolittle method; (iii) it is expressed at a high level in a human adult brain, and in less amount in the heart, while it is not expressed in other adult organs or fetus; (iv) it induces programmed cell death (apoptosis) when over-expressed in a cultured human nerve cell lines; (v) it induces termination of cell division and aging when over-expressed in a cultured human normal cell; (vi) it is located in cytoplasm, and forms an intracellular aggregate when overexpressed; and (vii) besides human adult neurons, it is specifically expressed in a human colorectal cancer cell line or in a skin cancer cell line, or an analogue thereof.